A phase III trial to study stage IV squamous cell lung cancer

IRB14-233
Cancer, Cancer - Lung
John McCann, MD
D'Amour Center for Cancer Care
3350 Main Street
Springfield, MA 01199
The purpose of this sub-study is to learn if the study drug will improve the average time to cancer worsening by more than a month. Nivolumab combined with ipilimumab is investigational for this study. Nivolumab combined with ipilimumab may or may not shrink your cancer but it could also cause side effects. This study will allow the researchers to learn any good and bad effects of nivolumab combined with ipilimumab.
Stage IV Squamous Cell Lung Cancer
Betsy Lopez
413-794-4154